| Literature DB >> 22455836 |
Zongbao Zheng1, Tao Chen, Meina Zhao, Zhiwen Wang, Xueming Zhao.
Abstract
BACKGROUND: The recalcitrant nature of hemicellulosic materials and the high cost in depolymerization are the primary obstacles preventing the use of xylan as feedstock for fuel and chemical production. Consolidated bioprocessing, incorporating enzyme-generating, biomass-degrading and bioproduct-producing capabilities into a single microorganism, could potentially avoid the cost of the dedicated enzyme generation in the process of xylan utilization. In this study, we engineered Escherichia coli strains capable of exporting three hemicellulases to the broth for the succinate production directly from beechwood xylan.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22455836 PMCID: PMC3340313 DOI: 10.1186/1475-2859-11-37
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Designations and sources of candidate xylanases
| Gene name | Preferred substrate | Protein Size (kDa) | Source organism | GenBank | Reference | |
|---|---|---|---|---|---|---|
| xylan | 45 | [ | ||||
| xylan | 44.3 | [ | ||||
| xylan | 28.2 | [ | ||||
| xylobiose | 38 | [ | ||||
| xylobiose | 56 | [ | ||||
| xylobiose | 61 | [ | ||||
| xylobiose | 42 | [ | ||||
The physiology and enzymatic properties of Z1EX0 series strains
| Strain | Xylanases expressed | Max OD600 | Protein secretion (g/l) | Endoxylanase activity | Xylosidase activity | |||
|---|---|---|---|---|---|---|---|---|
| 8 h(16 h)a | 24 h | (U/L) | (U/mg) | (U/L) | (mU/mg) | |||
| Bl21(DE3) | - | 6.50 ± 0.17 | 0.03 ± 0 | 0.03 ± 0 | n.d.b | n.d.b | n.d.b | n.d.b |
| Z1000 | - | 6.19 ± 0.08 | 0.04 ± 0 | 0.03 ± 0 | n.d.b | n.d.b | n.d.b | n.d.b |
| Z1140 | E1, X4 | 3.45 ± 0.04 | 0.30 ± 0.02 | 0.69 ± 0 | 398 ± 13 | 1.31 ± 0.07 | 24 ± 1.0 | 80 ± 4 |
| Z1150 | E1, X5 | 4.08 ± 0.12 | 0.19 ± 0.01 | 0.31 ± 0.03 | 65 ± 2 | 0.34 ± 0.01 | 14.3 ± 0.6 | 75 ± 4 |
| Z1160 | E1, X6 | 4.55 ± 0.05 | 0.10 ± 0.01 | 0.21 ± 0.02 | 75 ± 0 | 0.75 ± 0.04 | 6.1 ± 0.3 | 61 ± 5 |
| Z1170 | E1, X7 | 2.02 ± 0.05 | 0.60 ± 0.04 | 0.95 ± 0.03 | 420 ± 19 | 0.70 ± 0.04 | 46.3 ± 0.5 | 77 ± 3 |
| Z1240 | E2, X4 | 5.12 ± 0.12 | 0.10 ± 0.01 | 0.17 ± 0.01 | 274 ± 10 | 2.71 ± 0.19 | 8.0 ± 0.3 | 77 ± 6 |
| Z1250 | E2, X5 | 5.69 ± 0.29 | 0.11 ± 0.02 | 0.12 ± 0.03 | 50 ± 4 | 0.47 ± 0.03 | 6.8 ± 0.2 | 63 ± 7 |
| Z1260 | E2, X6 | 4.83 ± 0.05 | 0.07 ± 0 | 0.10 ± 0 | 90 ± 5 | 1.36 ± 0.04 | 4.5 ± 0.2 | 64 ± 1 |
| Z1270 | E2, X7 | 4.07 ± 0.05 | 0.34 ± 0.01 | 0.43 ± 0.02 | 423 ± 14 | 1.25 ± 0.04 | 29.3 ± 1.2 | 86 ± 3 |
| Z1340 | E3, X4 | 5.10 ± 0.03 | 0.08 ± 0.01 | 0.21 ± 0.01 | 1098 ± 28 | 13.22 ± 1.05 | 7.3 ± 0.2 | 88 ± 7 |
| Z1350 | E3, X5 | 3.97 ± 0.09 | 0.22 ± 0 | 0.51 ± 0.04 | 1512 ± 2 | 6.88 ± 0 | 10.9 ± 0.5 | 49 ± 1 |
| Z1360 | E3, X6 | 4.93 ± 0.10 | 0.08 ± 0 | 0.25 ± 0 | 996 ± 1 | 13.14 ± 0.01 | 5.9 ± 0.2 | 77 ± 1 |
| Z1370 | E3, X7 | 5.04 ± 0.05 | 0.18 ± 0.01 | 0.25 ± 0.01 | 2151 ± 14 | 12.14 ± 0.34 | 16.3 ± 0.2 | 92 ± 3 |
a Except maximum OD600, the sampling time was at the late-exponential phase, which was at about 8 h after induction for strains Z13X0 and the two controls, and 16 h for the other strains.
b n.d.: not detectable.
The physiology and enzymatic properties of the engineering strains with lpp deletion or dsbA overexpression
| Strain | Max. OD600 | Protein (g/l) | Endoxylanase activity | Xylosidase activity | |||
|---|---|---|---|---|---|---|---|
| Intracellular | Extracellular | (U/L) | (U/mg) | (U/L) | (mU/mg) | ||
| Z1370 | 5.04 ± 0.05 | 2.16 ± 0.11 | 0.18 ± 0.01 | 2151 ± 14 | 12.14 ± 0.34 | 16.3 ± 0.2 | 92 ± 3 |
| Z1371 | 2.09 ± 0.12 | 1.24 ± 0.07 | 0.41 ± 0.01 | 2919 ± 72 | 7.16 ± 0.17 | 31.8 ± 0.7 | 78 ± 2 |
| Z2370 | 4.43 ± 0.06 | 1.77 ± 0.04 | 0.21 ± 0.01 | 3024 ± 97 | 14.44 ± 0.62 | 20.7 ± 0.1 | 99 ± 3 |
Except maximum OD600, the sampling time was at the late-exponential phase, which was at about 8 h for the three strains.
Figure 1Protein profiles of the engineering strains. Cells were grown until OD600 reach 0.7 before IPTG was added to a final concentration of 0.5 mM, and incubation continued at 30°C. Samples were taken at 8 h after induction with IPTG. Proteins were separated on a 12% SDS-polyacrylamide gel.
The physiology and enzymatic properties of the engineering strains harboring a p15A-devirative plasmid
| Strain | Max. OD600 | Protein (g/l) | Endoxylanase activity | Xylosidase activity | |||
|---|---|---|---|---|---|---|---|
| Intracellular | Extracellular | (U/L) | (U/mg) | (U/L) | (mU/mg) | ||
| Z3370 | 5.49 ± 0.06 | 0.53 ± 0.03 | 0.16 ± 0.01 | 1945 ± 60 | 12.48 ± 0.57 | 15.0 ± 0.3 | 94 ± 4 |
| Z3371 | 2.86 ± 0.05 | 0.13 ± 0.02 | 0.32 ± 0.01 | 2022 ± 16 | 6.32 ± 0.12 | 22.7 ± 0.3 | 71 ± 2 |
| Z4370 | 5.75 ± 0.10 | 0.44 ± 0.02 | 0.18 ± 0.01 | 2581 ± 97 | 14.34 ± 0.67 | 17.0 ± 0.2 | 103 ± 3 |
Except maximum OD600, the sampling time was at the late-exponential phase, which was at about 8 h for the three strains.
Figure 2Cell density and unhydrolyzed sugars during cultivation of the engineered strains. Circle, Z3000; square, Z4370; triangle, Z5370; the solid symbols indicate OD600 and the hollow ones indicate unhydrolyzed sugars.
Figure 3Fermentation of Z6373 in different media.
Strains and plasmids used in this study
| Strain | Genotype | Source |
|---|---|---|
| Lab stocked | ||
| Novagen | ||
| Invitrogen | ||
| Z0001 | BL21 (DE3): Δ | This study |
| Z0003 | W1485: Δ | This study |
| Z1000 | BL21 (DE3): pTrc99z | This study |
| Z1EX0 | BL21 (DE3): pA-EmXn | This study |
| Z1371 | Z0001: pA-E3X7 | This study |
| Z2370 | BL21 (DE3): pA-E3X7D | This study |
| Z3000 | BL21 (DE3): pTrc15a | This study |
| Z3370 | BL21 (DE3): pB-E3X7 | This study |
| Z3371 | Z0001: pB-E3X7 | This study |
| Z4370 | BL21 (DE3): pB-E3X7D | This study |
| Z5370 | BL21 (DE3): pB-E3X7AD | This study |
| Z6373 | Z0003: pB-E3X7AYD | This study |
| pUC57-Em | pMB1 ori, | Genscript |
| pUC57-Xn | pMB1 ori, | Genscript |
| pUC57-EmXn series | pMB1 ori, | This study |
| pTrc99a | pBR322 ori, Ampr | Invitrogen |
| pTrc99z | pBR322 ori, Ampr | This study |
| pA-EmXn series | pBR322 ori, | This study |
| pA-E3X7D | pBR322 ori, | This study |
| pACYC184 | p15a ori, Catr Tetr | NEB |
| pTrc15a | p15a ori, Ampr | This study |
| pB-E3X7 | p15a ori, | This study |
| pB-E3X7D | p15a ori, | This study |
| pB-E3X7OD | p15a ori, | This study |
| pB-E3X7AD | p15a ori, | This study |
| pB-E3X7AYD | p15a ori, | This study |
Primers used in this study
| Primer name | DNA sequence (5'-3') |
|---|---|
| osmY-f | GCG |
| osmY-r | AAT |
| 99zD-f | ACATAC |
| 99zD-r | CGAC |
| trc-f | GCAG |
| trc-r | GTCGAC |
| dsb-f | GTACGAG |
| dsb-r | AGCGCAG |
| 184-f | GCAT |
| 184-r | CTAT |
| abf2-f | GCCA |
| abf2-r | GCCA |
| pyc-f | GCTG |
| pyc-r | CTGC |
Underlined nucleotides represent restriction sites.